Table 1 Comparison of baseline characteristics between diabetic and non-diabetic patients
Characteristic | Non-diabetics (n = 920) | Diabetics (n = 186) | p |
|---|---|---|---|
% (n/N) | % (n/N) | ||
Gender | 0.44 | ||
Female | 47.2 (434/920) | 46.2 (86/186) | |
Male | 52.8 (486/920) | 53.8 (100/186) | |
Age at diagnosis (mean) | <0.0001 | ||
Mean (SD) | 51.2 (13.1) | 64.5 (10.5) | |
Smoking history | 0.22 | ||
Non-smoker | 40.7 (374/920) | 44.1 (82/186) | |
Smoker | 59.3 (546/920) | 55.9 (104/186) | |
Histology | 0.48 | ||
Adenocarcinoma | 68.3 (628/920) | 67.7 (126/186) | |
Other | 31.7 (292/920) | 32.3 (60/186) | |
Disease Stage | 0.36 | ||
II-IIIa | 5.5 (51/920) | 6.5 (12/186) | |
IIIb-IV | 94.5 (869/920) | 93.5 (174/186) | |
ECOG PS | 0.31 | ||
0–1 | 74.5(685/920) | 78 (145/186) | |
2–4 | 25.5 (235/920) | 22 (41/186) | |
CNS metastases at diagnosis | 0.09 | ||
Absent | 53.5 (492/920) | 47.8 (89/186) | |
Present | 46.5 (428/920) | 52.2 (97/186) | |
Basal Glucose | <0.0001 | ||
Mean (SD) | 105 (14.5) | 170 (78.5) | |
EGFR mutation (n = 417) | 0.09 | ||
Positive | 34.9 (123/352) | 44.6 (29/65) | |
Negative | 65.1 (229/352) | 55.4 (36/65) | |
KRAS mutation (n = 184) | 0.60 | ||
Positive | 16.3. (25/30) | 16.7 (5/31) | |
Negative | 83.7 (128/153) | 83.9 (26/31) |